Bas L R Mandos

Sex-based survival disparities in patients with stage I–III non-small cell lung cancer vary by treatment modality

Guus R. M. van den Heuvel, Bas L R Mandos, Hans J.M. Smit, Olga C.J. Schuurbiers et autres

Introduction Female sex is a well-established prognostic factor in non-small cell lung cancer (NSCLC). Most prior studies are restricted to single-treatment cohorts and seldom include best supportive care (BSC), limiting the evaluation of sex-based median overall survival across the full treatment spectrum, …

nl, us (code pays fourni par la source)

Best supportive care in stage I–III non-small cell lung cancer: survival by reason for curative treatment omission in a real-world study population

Guus R. M. van den Heuvel, Bas L R Mandos, Hans J.M. Smit, Olga C.J. Schuurbiers et autres

Background: Despite advances in stage I-III non-small cell lung cancer (NSCLC) treatment, curative-intent therapy is withheld in patients deemed ineligible or preferring no treatment. Limited real-world data exist on overall and cancer-related survival outcomes in patients receiving primary best supportive care (BSC). …

nl (code pays fourni par la source)

Inoperable POLE-mutated endometrial carcinoma: treatment beyond current guidelines

Bas L R Mandos, Sander Kelderman, Janneke E. W. Walraven, Heidi Rütten et autres

nl (code pays fourni par la source)

Absent preoperative non-small cell lung cancer confirmation and relevant stage migration in the era before neoadjuvant chemoimmunotherapy: implications for treatment decisions in resectable non-small cell lung cancer

Guus R. M. van den Heuvel, Bas L R Mandos, Olga C.J. Schuurbiers, Francesco Ciompi et autres

Background: Achieving preoperative pathological confirmation and accurate clinical staging are crucial for neoadjuvant treatment decisions in resectable non-small cell lung cancer (NSCLC), though often challenging. This study examines the prevalence of missing preoperative pathological confirmation with focus on patients with clinical stage …

nl (code pays fourni par la source)

Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study

Milou M. F. Schuurbiers, Christopher G. Smith, Koen Johan Hartemink, Robert Campbell Rintoul et autres

BACKGROUND: Despite treatment with curative intent, many patients with localized non-small cell lung cancer (NSCLC) develop recurrence. The current challenge is to identify high-risk patients to guide adjuvant treatment. Identification of residual disease by detection of circulating tumor DNA (ctDNA) may allow …

nl, us, gb (code pays fourni par la source)

Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4

Mylène Gerritsen, Florentien E. M. in ’t Hout, Ruth Knops, Bas L R Mandos et autres

nl, de (code pays fourni par la source)

1234P Stage migration in resectable NSCLC

G. Van den Heuvel, Bas L R Mandos, Olga C.J. Schuurbiers, Erik H.J.G. Aarntzen et autres

nl (code pays fourni par la source)